Henlius and Sandoz Expand Biosimilar Partnership in Global Deal

The deal encompasses three initial products—cetuximab, evolocumab, and belimumab biosimilars—alongside an option for a recombinant human hyaluronidase asset. Under the terms, Henlius will leverage its integrated biologics platform to handle development and manufacturing, while Sandoz utilizes its extensive global reach to manage regulatory submissions and commercialization. The financial scope of the agreement includes an upfront payment, milestone payments, and an option fee totaling up to US$322 million. For the 2026 fiscal year, Henlius anticipates an invoiced amount of up to US$100.5 million.

This move serves as a cornerstone of Henlius’ globalization strategy, validating its R&D and manufacturing standards. By integrating Sandoz’s market insights into the early stages of project development, the companies aim to streamline the transition from the laboratory to global clinical application. The collaboration covers key regions including the United States, Canada, the European Union, and several major markets across Asia and the Pacific. Both firms intend to synchronize their efforts across the entire product lifecycle to secure competitive positioning in the global biosimilars landscape.